PRPH
ProPhase Labs, Inc.NASDAQHealthcare$0.09+2.87%ClosedMarket Cap: $426,331
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.05
P/S
0.36
EV/EBITDA
-0.31
DCF Value
$-12.72
FCF Yield
-5828.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
191.4%
Operating Margin
-2496.6%
Net Margin
-3872.2%
ROE
-404.4%
ROA
-63.5%
ROIC
-156.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $883.0K | -13.9% | $-4.8M | $-6.8M | $-1.60 | — |
| Q2 2025 | $1.2M | 58.9% | $-3.9M | $-4.5M | $-1.10 | — |
| Q1 2025 | $1.4M | 36.8% | $-3.7M | $4.0M | $2.10 | — |
| Q4 2024 | $-2.5M | -37.2% | $-14.6M | $-34.4M | $-15.80 | — |
| FY 2024 | $6.8M | -2.2% | $-38.6M | $-53.4M | $-26.10 | — |
| Q3 2024 | $3.1M | -5.2% | $-7.9M | $-6.6M | $-3.50 | — |
| Q2 2024 | $2.5M | -19.2% | $-7.8M | $-6.2M | $-3.30 | — |
| Q1 2024 | $3.6M | -11.9% | $-8.3M | $-6.3M | $-3.50 | — |
| Q4 2023 | $3.5M | -87.3% | $-11.4M | $-8.8M | $-4.80 | — |
| FY 2023 | $44.4M | 36.6% | $-21.6M | $-16.8M | $-9.80 | — |
| Q3 2023 | $8.4M | 27.8% | $-6.5M | $-5.1M | $-3.00 | — |
| Q2 2023 | $13.2M | 48.8% | $-4.7M | $-3.4M | $-2.00 | — |